⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for pharmacogenomic study

Every month we try and update this database with for pharmacogenomic study cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast CancerNCT02453620
Anatomic Stage ...
Anatomic Stage ...
Breast Adenocar...
Invasive Breast...
Malignant Solid...
Biopsy
Blood Sample
Bone Scan
Computed Tomogr...
Entinostat
Ipilimumab
Nivolumab
Pharmacogenomic...
Pharmacological...
Positron Emissi...
18 Years - National Cancer Institute (NCI)
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous MelanomaNCT02581930
Metastatic Mela...
Recurrent Cutan...
Stage IV Cutane...
Ibrutinib
Laboratory Biom...
Pharmacogenomic...
Pharmacological...
18 Years - National Cancer Institute (NCI)
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast CancerNCT02453620
Anatomic Stage ...
Anatomic Stage ...
Breast Adenocar...
Invasive Breast...
Malignant Solid...
Biopsy
Blood Sample
Bone Scan
Computed Tomogr...
Entinostat
Ipilimumab
Nivolumab
Pharmacogenomic...
Pharmacological...
Positron Emissi...
18 Years - National Cancer Institute (NCI)
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT02048813
Anemia
Chronic Lymphoc...
Small Lymphocyt...
Cyclophosphamid...
Fludarabine Pho...
Ibrutinib
Laboratory Biom...
Pharmacogenomic...
Quality-of-Life...
Rituximab
18 Years - 70 YearsNational Cancer Institute (NCI)
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT02048813
Anemia
Chronic Lymphoc...
Small Lymphocyt...
Cyclophosphamid...
Fludarabine Pho...
Ibrutinib
Laboratory Biom...
Pharmacogenomic...
Quality-of-Life...
Rituximab
18 Years - 70 YearsNational Cancer Institute (NCI)
HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent GlioblastomaNCT03216499
Recurrent Gliob...
HIF-2alpha Inhi...
Pharmacological...
Laboratory Biom...
Pharmacogenomic...
18 Years - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pembrolizumab in Treating Patients With Malignant MesotheliomaNCT02399371
Biphasic Mesoth...
Epithelioid Mes...
Peritoneal Mali...
Pleural Biphasi...
Pleural Epithel...
Pleural Maligna...
Pleural Sarcoma...
Recurrent Perit...
Recurrent Pleur...
Sarcomatoid Mes...
Pembrolizumab
Laboratory Biom...
Pharmacogenomic...
18 Years - University of Chicago
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by SurgeryNCT00381641
Differentiated ...
Recurrent Thyro...
Refractory Thyr...
Stage III Thyro...
Stage III Thyro...
Stage IV Thyroi...
Stage IV Thyroi...
Stage IV Thyroi...
Stage IVA Thyro...
Stage IVA Thyro...
Stage IVA Thyro...
Stage IVB Thyro...
Stage IVB Thyro...
Stage IVB Thyro...
Stage IVC Thyro...
Stage IVC Thyro...
Stage IVC Thyro...
Thyroid Gland O...
Unresectable Th...
Laboratory Biom...
Pharmacogenomic...
Sunitinib
Sunitinib Malat...
18 Years - National Cancer Institute (NCI)
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaNCT02443077
Recurrent Diffu...
Refractory Diff...
Autologous Bone...
Autologous Hema...
Carmustine
Cyclophosphamid...
Cytarabine
Etoposide
Ibrutinib
Laboratory Biom...
Melphalan
Pharmacogenomic...
Placebo Adminis...
18 Years - National Cancer Institute (NCI)
Carvedilol in Preventing Heart Failure in Childhood Cancer SurvivorsNCT02717507
Hematopoietic a...
Malignant Solid...
Carvedilol
Laboratory Biom...
Pharmacogenomic...
Pharmacological...
Placebo Adminis...
Quality-of-Life...
Questionnaire A...
- Children's Oncology Group
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: